Liraglutide Outperforms Metformin for Weight Loss in Obese PCOS Women

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting women, characterized by hormonal imbalances, ovulatory dysfunction, and often obesity and insulin resistance. These conditions collectively increase risks for metabolic complications and reduce quality of life. While metformin is a common treatment, this study aimed to determine if liraglutide could offer superior short-term improvements in body weight for obese women newly diagnosed with PCOS.

Consistent with the study's primary objective and anticipation, liraglutide demonstrated a significantly greater impact on body weight reduction compared to metformin. Participants receiving liraglutide achieved an average weight loss of 5.2 kg, representing a 6.5% reduction from baseline body weight over the 12-week period. In contrast, the metformin group experienced a more modest average weight loss of 2.1 kg, or a 2.8% reduction from baseline. This difference was statistically highly significant, indicating a clear advantage for the GLP-1 agonist. > The liraglutide treatment led to a 2.5-fold greater body weight reduction compared to metformin over the 12-week study duration (p<0.001). While not explicitly detailed in the provided summary, such significant weight loss in PCOS patients is often accompanied by improvements in insulin sensitivity and hormonal profiles, which are critical for managing the syndrome's broader metabolic complications.